Pfizer is targeting air traffic control agencies in Poland and Romania to enforce a Belgian court ruling ordering the two countries to accept €1.9 billion worth of COVID-19 vaccines they refused to take delivery of after pandemic-era demand waned.
AbbVie announced positive Phase 3 results for etentamig, a dual-acting T cell engager for multiple myeloma, showing survival benefits with a cleaner safety profile compared to competing BCMA-targeting therapies from Johnson & Johnson, Pfizer and Regeneron. The company is seeking to enter the crowded multiple myeloma treatment market.
The Kenyan government has reached an agreement with US pharmaceutical company Pfizer that will reduce the cost of cancer medications by more than sevenfold, according to President William Ruto. The deal is expected to significantly lower treatment costs for cancer patients across the country.
Pfizer announced positive topline results from two pivotal Phase 3 studies showing LITFULO (ritlecitinib) significantly improved facial and total repigmentation compared to placebo at 52 weeks in patients with nonsegmental vitiligo. The studies represent the largest Phase 3 program to date for an oral systemic therapy in this indication.
GLP-1 drugs from Pfizer and Innovent Biologics have cleared preliminary review to potentially be included in China's basic medical insurance drug catalogue, which would expand access to these treatments.
The FDA approved Kresladi, Rocket Pharmaceuticals' gene therapy for a rare immune disorder, despite testing in only nine patients. The approval represents a notable decision as the agency has recently taken tougher stances on rare disease drugs.
